Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat

Stacey Quintero Wolfe, Megha Garg, Nadia M A Cumberbatch, Cassandra Furst, Miguel Martinez, Massiel Hernandez, Regine Reimers, Yerko Berrocal, Orlando W Gomez-Marin, Mary J. Eaton

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Neuropathic pain is a prevalent and difficult problem in the setting of spinal cord injury (SCI). The use of cellular transplant therapy to treat this pain has been successful with the use of a human neuronal cell line, hNT2.17 [M.J. Eaton, S.Q. Wolfe, M.A. Martinez, M. Hernandez, C. Furst, J. Huang, B.R. Frydel, O. Gomez-Marin, Subarachnoid transplant of a human neuronal cell line attenuates chronic allodynia and hyperalgesia after excitotoxic SCI in the rat, J. Pain 8 (2007) 33-50]. Intrathecal transplant of these cells potently reverses behavioral hypersensitivity after excitotoxic spinal cord injury in the rat model. This study focuses on delineating the optimal dose of these cell grafts in the same model. Two weeks after intraspinal injection of quisqualic acid (QUIS) with subsequent behavioral hypersensitivity, terminally differentiated hNT2.17 cells were transplanted into 300 g Wistar-Furth rats in a logarithmic variation of doses: 106, 105 and 103 cells. Behavioral hypersensitivity testing was performed weekly for 6 weeks following transplant. The dose of 106 cells (or approximately 3 million/kg) potently and permanently reversed both cutaneous allodynia (CA) and thermal hyperalgesia (TH). Reduced transplant doses of the hNT2.17 cell line did not permanently reverse behavioral hypersensitivity, suggesting that there is an optimal dose that can be used as a clinical tool to treat SCI-associated neuropathic pain.

Original languageEnglish
Pages (from-to)121-125
Number of pages5
JournalNeuroscience Letters
Volume414
Issue number2
DOIs
StatePublished - Mar 6 2007

Fingerprint

Spinal Cord Injuries
Hyperalgesia
Transplants
Pain
Cell Line
Hypersensitivity
Neuralgia
Inbred WF Rats
Quisqualic Acid
Spinal Injections
Skin

Keywords

  • Cellular transplant
  • hNT2.17
  • Intrathecal dose
  • Neuronal cell line
  • Neuropathic pain
  • Spinal cord injury

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Wolfe, S. Q., Garg, M., Cumberbatch, N. M. A., Furst, C., Martinez, M., Hernandez, M., ... Eaton, M. J. (2007). Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat. Neuroscience Letters, 414(2), 121-125. https://doi.org/10.1016/j.neulet.2006.10.067

Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat. / Wolfe, Stacey Quintero; Garg, Megha; Cumberbatch, Nadia M A; Furst, Cassandra; Martinez, Miguel; Hernandez, Massiel; Reimers, Regine; Berrocal, Yerko; Gomez-Marin, Orlando W; Eaton, Mary J.

In: Neuroscience Letters, Vol. 414, No. 2, 06.03.2007, p. 121-125.

Research output: Contribution to journalArticle

Wolfe, SQ, Garg, M, Cumberbatch, NMA, Furst, C, Martinez, M, Hernandez, M, Reimers, R, Berrocal, Y, Gomez-Marin, OW & Eaton, MJ 2007, 'Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat', Neuroscience Letters, vol. 414, no. 2, pp. 121-125. https://doi.org/10.1016/j.neulet.2006.10.067
Wolfe SQ, Garg M, Cumberbatch NMA, Furst C, Martinez M, Hernandez M et al. Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat. Neuroscience Letters. 2007 Mar 6;414(2):121-125. https://doi.org/10.1016/j.neulet.2006.10.067
Wolfe, Stacey Quintero ; Garg, Megha ; Cumberbatch, Nadia M A ; Furst, Cassandra ; Martinez, Miguel ; Hernandez, Massiel ; Reimers, Regine ; Berrocal, Yerko ; Gomez-Marin, Orlando W ; Eaton, Mary J. / Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat. In: Neuroscience Letters. 2007 ; Vol. 414, No. 2. pp. 121-125.
@article{21019073af7743d7a34813c43efbd3a7,
title = "Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat",
abstract = "Neuropathic pain is a prevalent and difficult problem in the setting of spinal cord injury (SCI). The use of cellular transplant therapy to treat this pain has been successful with the use of a human neuronal cell line, hNT2.17 [M.J. Eaton, S.Q. Wolfe, M.A. Martinez, M. Hernandez, C. Furst, J. Huang, B.R. Frydel, O. Gomez-Marin, Subarachnoid transplant of a human neuronal cell line attenuates chronic allodynia and hyperalgesia after excitotoxic SCI in the rat, J. Pain 8 (2007) 33-50]. Intrathecal transplant of these cells potently reverses behavioral hypersensitivity after excitotoxic spinal cord injury in the rat model. This study focuses on delineating the optimal dose of these cell grafts in the same model. Two weeks after intraspinal injection of quisqualic acid (QUIS) with subsequent behavioral hypersensitivity, terminally differentiated hNT2.17 cells were transplanted into 300 g Wistar-Furth rats in a logarithmic variation of doses: 106, 105 and 103 cells. Behavioral hypersensitivity testing was performed weekly for 6 weeks following transplant. The dose of 106 cells (or approximately 3 million/kg) potently and permanently reversed both cutaneous allodynia (CA) and thermal hyperalgesia (TH). Reduced transplant doses of the hNT2.17 cell line did not permanently reverse behavioral hypersensitivity, suggesting that there is an optimal dose that can be used as a clinical tool to treat SCI-associated neuropathic pain.",
keywords = "Cellular transplant, hNT2.17, Intrathecal dose, Neuronal cell line, Neuropathic pain, Spinal cord injury",
author = "Wolfe, {Stacey Quintero} and Megha Garg and Cumberbatch, {Nadia M A} and Cassandra Furst and Miguel Martinez and Massiel Hernandez and Regine Reimers and Yerko Berrocal and Gomez-Marin, {Orlando W} and Eaton, {Mary J.}",
year = "2007",
month = "3",
day = "6",
doi = "10.1016/j.neulet.2006.10.067",
language = "English",
volume = "414",
pages = "121--125",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat

AU - Wolfe, Stacey Quintero

AU - Garg, Megha

AU - Cumberbatch, Nadia M A

AU - Furst, Cassandra

AU - Martinez, Miguel

AU - Hernandez, Massiel

AU - Reimers, Regine

AU - Berrocal, Yerko

AU - Gomez-Marin, Orlando W

AU - Eaton, Mary J.

PY - 2007/3/6

Y1 - 2007/3/6

N2 - Neuropathic pain is a prevalent and difficult problem in the setting of spinal cord injury (SCI). The use of cellular transplant therapy to treat this pain has been successful with the use of a human neuronal cell line, hNT2.17 [M.J. Eaton, S.Q. Wolfe, M.A. Martinez, M. Hernandez, C. Furst, J. Huang, B.R. Frydel, O. Gomez-Marin, Subarachnoid transplant of a human neuronal cell line attenuates chronic allodynia and hyperalgesia after excitotoxic SCI in the rat, J. Pain 8 (2007) 33-50]. Intrathecal transplant of these cells potently reverses behavioral hypersensitivity after excitotoxic spinal cord injury in the rat model. This study focuses on delineating the optimal dose of these cell grafts in the same model. Two weeks after intraspinal injection of quisqualic acid (QUIS) with subsequent behavioral hypersensitivity, terminally differentiated hNT2.17 cells were transplanted into 300 g Wistar-Furth rats in a logarithmic variation of doses: 106, 105 and 103 cells. Behavioral hypersensitivity testing was performed weekly for 6 weeks following transplant. The dose of 106 cells (or approximately 3 million/kg) potently and permanently reversed both cutaneous allodynia (CA) and thermal hyperalgesia (TH). Reduced transplant doses of the hNT2.17 cell line did not permanently reverse behavioral hypersensitivity, suggesting that there is an optimal dose that can be used as a clinical tool to treat SCI-associated neuropathic pain.

AB - Neuropathic pain is a prevalent and difficult problem in the setting of spinal cord injury (SCI). The use of cellular transplant therapy to treat this pain has been successful with the use of a human neuronal cell line, hNT2.17 [M.J. Eaton, S.Q. Wolfe, M.A. Martinez, M. Hernandez, C. Furst, J. Huang, B.R. Frydel, O. Gomez-Marin, Subarachnoid transplant of a human neuronal cell line attenuates chronic allodynia and hyperalgesia after excitotoxic SCI in the rat, J. Pain 8 (2007) 33-50]. Intrathecal transplant of these cells potently reverses behavioral hypersensitivity after excitotoxic spinal cord injury in the rat model. This study focuses on delineating the optimal dose of these cell grafts in the same model. Two weeks after intraspinal injection of quisqualic acid (QUIS) with subsequent behavioral hypersensitivity, terminally differentiated hNT2.17 cells were transplanted into 300 g Wistar-Furth rats in a logarithmic variation of doses: 106, 105 and 103 cells. Behavioral hypersensitivity testing was performed weekly for 6 weeks following transplant. The dose of 106 cells (or approximately 3 million/kg) potently and permanently reversed both cutaneous allodynia (CA) and thermal hyperalgesia (TH). Reduced transplant doses of the hNT2.17 cell line did not permanently reverse behavioral hypersensitivity, suggesting that there is an optimal dose that can be used as a clinical tool to treat SCI-associated neuropathic pain.

KW - Cellular transplant

KW - hNT2.17

KW - Intrathecal dose

KW - Neuronal cell line

KW - Neuropathic pain

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=33847016417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847016417&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2006.10.067

DO - 10.1016/j.neulet.2006.10.067

M3 - Article

C2 - 17306458

AN - SCOPUS:33847016417

VL - 414

SP - 121

EP - 125

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -